Fayez Sarofim & Co
AZN icon

Fayez Sarofim & Co’s AstraZeneca AZN Stock Holding History

Fayez Sarofim & Co’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1M Buy
+179,593
New +$33.8M 0.08% 71
2026
Q1 		– Sell
-2,129,320
Closed -$391M – 295
2025
Q4 		$391M Buy
2,129,320
+182,101
+9% +$31.9M 0.94% 31
2025
Q3 		$299M Buy
1,947,219
+74,268
+4% +$11.2M 0.69% 41
2025
Q2 		$262M Buy
1,872,951
+1,188,016
+173% +$166M 0.63% 44
2025
Q1 		$272M Sell
684,935
-1,136,570
-62% -$164M 0.68% 43
2024
Q4 		$239M Buy
1,821,505
+99,488
+6% +$13.9M 0.58% 48
2024
Q3 		$268M Buy
1,722,017
+102,429
+6% +$16.5M 0.68% 43
2024
Q2 		$253M Buy
1,619,588
+124,471
+8% +$18.7M 0.68% 43
2024
Q1 		$203M Buy
1,495,117
+67,392
+5% +$8.92M 0.6% 48
2023
Q4 		$178M Buy
1,427,725
+373,617
+35% +$48.6M 0.54% 49
2023
Q3 		$143M Buy
1,054,108
+280,467
+36% +$38.3M 0.48% 54
2023
Q2 		$111M Buy
773,641
+257,377
+50% +$37.9M 0.39% 56
2023
Q1 		$71.7M Buy
516,264
+503,916
+4,081% +$67.8M 0.25% 62
2022
Q4 		$1.67M Buy
+12,348
New +$1.55M 0.01% 151
2022
Q3 		– Sell
-1,673
Closed -$221K – 279
2022
Q2 		$221K Buy
+1,673
New +$220K ﹤0.01% 282

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fayez Sarofim & Co's AZN Position: Q2 2026 in Review

Fayez Sarofim & Co opened a new position in AstraZeneca (AZN) in Q2 2026: 179,593 shares worth $34.1M. The stake represents 0.08% of the portfolio and ranks #71 among its holdings. This is a return to the name: Fayez Sarofim & Co previously reported a position in AZN as recently as Q4 2025.

Fayez Sarofim & Co first reported a position in AZN in Q2 2022 and has held it in 15 quarters since. The position peaked at $391M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Fayez Sarofim & Co held 179,593 shares of AstraZeneca worth $34.1M as of Q2 2026.
  • AstraZeneca was a new Fayez Sarofim & Co position in Q2 2026.
  • AstraZeneca made up 0.08% of Fayez Sarofim & Co's portfolio in Q2 2026, its #71 holding.
  • Fayez Sarofim & Co first reported a position in AstraZeneca in Q2 2022 and has held it in 15 quarters since.
  • Fayez Sarofim & Co's AstraZeneca position peaked at $391M in Q4 2025.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Fayez Sarofim & Co's 13F filing for Q2 2026, filed 17 Aug 2026.